{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T19:40:10.766587+00:00","company":{"ticker":"PTGX","cik":1377121,"company_name":"Protagonist Therapeutics, Inc"},"pagination":{"limit":100,"returned":6,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"cb3c070e215e6684171cff22d170c2b75df5379b","cik":1377121,"ticker":"PTGX","company_name":"Protagonist Therapeutics, Inc","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":"Diluted earnings (loss) per share $ 0.05","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net income (loss) $ 3,783","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-05","result_type":"reported_results","revenue_text":"License and collaboration revenue $ 56,368"},"claim":"Protagonist Therapeutics, Inc reported first quarter ended March 31, 2026 results: revenue License and collaboration revenue $ 56,368, net income Net income (loss) $ 3,783, EPS Diluted earnings (loss) per share $ 0.05.","evidence_excerpt":"to $646.0 million as of December 31, 2025. Three Months Ended March 31, 2026 2025 (in thousands, except per share amounts) (Unaudited) License and collaboration revenue $ 56,368 $ 28,321 Research and development expense $ 46,739 $ 35,893 General and administrative expense $ 13,277 $ 11,738 Income tax benefit $ 1,502 $ - Net income (loss) $ 3,783 $ (11,655","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-26-055629","anchor_url":"https://secwatch.observer/filing/0001104659-26-055629#claim-cb3c070e215e6684171cff22d170c2b75df5379b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926055629/0001104659-26-055629-index.htm"},{"fact_type":"executive_change","fact_key":"6527c83d83","cik":1377121,"ticker":"PTGX","company_name":"Protagonist Therapeutics, Inc","filed_at":"2025-01-06T23:59:59+00:00","payload":{"action":"transitioned","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-01-01","interim":false,"role":"Executive Vice President, Clinical Development","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Suneel Gupta changed role as Executive Vice President, Clinical Development at Protagonist Therapeutics, Inc.","evidence_excerpt":"Effective January 1, 2025, Suneel Gupta, Ph.D., Protagonist Therapeutics, Inc.’s Chief Development Officer, transitioned to Executive Vice President, Clinical Development.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-001304","anchor_url":"https://secwatch.observer/filing/0001104659-25-001304#claim-6527c83d83","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925001304/0001104659-25-001304-index.htm"},{"fact_type":"executive_change","fact_key":"bd434f70d4","cik":1377121,"ticker":"PTGX","company_name":"Protagonist Therapeutics, Inc","filed_at":"2024-09-20T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-09-17","interim":false,"role":"Member of the Board of Directors","role_category":"director","successor_name":null,"successor_named":false},"claim":"Daniel N. Swisher Jr. resigned as Member of the Board of Directors at Protagonist Therapeutics, Inc.","evidence_excerpt":"On September 17, 2024, Daniel N. Swisher Jr., a member of the Board of Directors (the “Board”) of Protagonist Therapeutics, Inc. (the “Company”) and a member of the Audit Committee of the Board, resigned from the Board, effective September 17, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-24-101688","anchor_url":"https://secwatch.observer/filing/0001104659-24-101688#claim-bd434f70d4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924101688/0001104659-24-101688-index.htm"},{"fact_type":"earnings_release","fact_key":"27b0f7df56e9e133dd64025deb6417dc38e8fc42","cik":1377121,"ticker":"PTGX","company_name":"Protagonist Therapeutics, Inc","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":"$3.26 per diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$207,340 thousand","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":"$255.0 million"},"claim":"Protagonist Therapeutics, Inc reported first quarter ended March 31, 2024 results: revenue $255.0 million, net income $207,340 thousand, EPS $3.26 per diluted share.","evidence_excerpt":") Basic earnings (loss) per share $ 3.41 $ (0.67 ) Diluted earnings (loss) per share $ 3.26 $ (0.67 ) · License and Collaboration Revenue : License and collaboration revenue of $255.0 million for March 31, 2024 consisted of:\n(i) $254.1 million of the $300.0 million transaction price for the Takeda Collaboration Agreement allocated to the rusfertide license\ndelivered","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-058036","anchor_url":"https://secwatch.observer/filing/0001104659-24-058036#claim-27b0f7df56e9e133dd64025deb6417dc38e8fc42","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924058036/0001104659-24-058036-index.htm"},{"fact_type":"earnings_release","fact_key":"369e4572ea07b01b386058b95db713cd0f85eb60","cik":1377121,"ticker":"PTGX","company_name":"Protagonist Therapeutics, Inc","filed_at":"2024-02-27T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and full year ended December 31, 2023","report_date":"2024-02-27","result_type":"reported_results","revenue_text":null},"claim":"Protagonist Therapeutics, Inc reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On February 27, 2024, Protagonist Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2023.","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001104659-24-028208","anchor_url":"https://secwatch.observer/filing/0001104659-24-028208#claim-369e4572ea07b01b386058b95db713cd0f85eb60","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924028208/0001104659-24-028208-index.htm"},{"fact_type":"material_agreement","fact_key":"542d2c40c01e4e49a8d6a5a23043815392ccb0cb","cik":1377121,"ticker":"PTGX","company_name":"Protagonist Therapeutics, Inc","filed_at":"2024-01-31T23:59:59+00:00","payload":{"action":"entry","agreement_name":"License and Collaboration Agreement","agreement_type":"collaboration","counterparty":"Takeda Pharmaceuticals USA, Inc.","effective_date":"2024-01-31","item_codes_triggered":["1.01"],"value_text":"$300 million"},"claim":"Protagonist Therapeutics, Inc entered into License and Collaboration Agreement with Takeda Pharmaceuticals USA, Inc. valued at $300 million (effective 2024-01-31).","evidence_excerpt":"On January 31, 2024, Protagonist Therapeutics, Inc. (the “ Company ”) entered into a License and Collaboration Agreement (the “ Collaboration Agreement ”) with Takeda Pharmaceuticals USA, Inc. (“ Takeda ”) for the development, manufacture and commercialization of the Company’s rusfertide product candidate","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-008787","anchor_url":"https://secwatch.observer/filing/0001104659-24-008787#claim-542d2c40c01e4e49a8d6a5a23043815392ccb0cb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924008787/0001104659-24-008787-index.htm"}]}